3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Myelodysplastic Syndromes
1
Muscle Invasive Bladder Cancer
1
Leukemia, Myeloid, Acute
1
Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck
1
Interventions
pembrolizumab
243
Carboplatin
211
Pemetrexed
177
Cisplatin
131
Paclitaxel
113
Nivolumab
101
Docetaxel
87
osimertinib
85
durvalumab
78
Specimen Handling
56
atezolizumab
55
Gemcitabine
52
Drug Therapy
52
Magnetic Resonance Spectroscopy
50
Radiosurgery
48
Radiotherapy
47
Ipilimumab
41
130-nm albumin-bound paclitaxel
39
cemiplimab
38
Bevacizumab
34
Cetuximab
30
tislelizumab
29
amivantamab
22
Taxes
22
Platinum Compounds
20
Blood Specimen Collection
20
Immunotherapy
18
Immune Checkpoint Inhibitors
18
Radiation
17
Erlotinib Hydrochloride
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Carcinoma, Non-Small-Cell Lung
×
danvatirsen
×
1 year
×
Clear all
NCT03819465
2026-05-12
MAGELLAN
AstraZeneca
Phase 1
Active not recruiting
175 enrolled
NCT03334617
2025-10-27
HUDSON
AstraZeneca
Phase 2
Active not recruiting
528 enrolled
16 charts